Biotech News
MacroGenics Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate Progress
Completed MGC028 Phase 1 dose escalation; selected lead indication for dose optimization across two dose levels Reported interim results at ESMO in both Phase 1 study of MGC026 in heavily pretreated SCCHN patients and Phase 2 study of lorigerlimab in CCGC patients First patient dosed with MGC030 in
